Informations générales (source: ClinicalTrials.gov)

NCT03807128 En recrutement
MYeloma Resistance And Clonal Evolution
Observational
  • Myélome multiple
  • Tumeurs à plasmocytes
Nantes University Hospital (Voir sur ClinicalTrials)
février 2019
février 2049
17 septembre 2025
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Nantes University Hospital - 44093 - Nantes - France Cyrille TOUZEAU, PU En recrutement Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
La Roche sur Yon Hospital Departmental - 85000 - La Roche-sur-Yon - France En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Patient consulting due to the discovery or recurrence of MM according to
international diagnostic criteria (IMWG 2014)

- Patient having consented to participate in the study and his/her biocollection

- Patient affiliated to or benefiting from a social security scheme or similar


- Minors

- Major under guardianship or curatorship

- Protected persons.

- Pregnant or breast-feeding women

- Persons benefiting from the AME